- Home
- QQQX vs NRIX Comparison
QQQX vs NRIX Comparison
Compare QQQX & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QQQX
- NRIX
- Stock Information
- Founded
- QQQX 2007
- NRIX 2009
- Country
- QQQX United States
- NRIX United States
- Employees
- QQQX N/A
- NRIX N/A
- Industry
- QQQX Finance Companies
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- QQQX Finance
- NRIX Health Care
- Exchange
- QQQX Nasdaq
- NRIX Nasdaq
- Market Cap
- QQQX 1.2B
- NRIX 1.1B
- IPO Year
- QQQX N/A
- NRIX 2020
- Fundamental
- Price
- QQQX $22.38
- NRIX $10.24
- Analyst Decision
- QQQX
- NRIX Strong Buy
- Analyst Count
- QQQX 0
- NRIX 18
- Target Price
- QQQX N/A
- NRIX $30.39
- AVG Volume (30 Days)
- QQQX 127.6K
- NRIX 1.3M
- Earning Date
- QQQX 01-01-0001
- NRIX 04-08-2025
- Dividend Yield
- QQQX 7.03%
- NRIX N/A
- EPS Growth
- QQQX N/A
- NRIX N/A
- EPS
- QQQX N/A
- NRIX N/A
- Revenue
- QQQX N/A
- NRIX $56,417,000.00
- Revenue This Year
- QQQX N/A
- NRIX $12.84
- Revenue Next Year
- QQQX N/A
- NRIX N/A
- P/E Ratio
- QQQX N/A
- NRIX N/A
- Revenue Growth
- QQQX N/A
- NRIX N/A
- 52 Week Low
- QQQX $20.27
- NRIX $8.18
- 52 Week High
- QQQX $25.99
- NRIX $29.56
- Technical
- Relative Strength Index (RSI)
- QQQX 41.29
- NRIX 39.72
- Support Level
- QQQX $20.34
- NRIX $9.23
- Resistance Level
- QQQX $23.60
- NRIX $10.17
- Average True Range (ATR)
- QQQX 1.07
- NRIX 1.04
- MACD
- QQQX 0.08
- NRIX 0.15
- Stochastic Oscillator
- QQQX 53.12
- NRIX 53.51
About QQQX Nuveen NASDAQ 100 Dynamic Overwrite Fund Shares of Beneficial Interest
Nuveen NASDAQ 100 Dynamic Overwrite Fund is a closed-end management investment company. Its investment objective is to seek an attractive total return with less volatility than the Nasdaq 100 Index. Under normal circumstances, the Fund will invest at least 80% of its Assets in an equity portfolio made up of securities comprising the Nasdaq 100 Index (or securities that have economic characteristics that are similar to those securities comprising the Nasdaq 100 Index) that seeks to substantially replicate price movements of the Nasdaq 100 Index and is designed to support the Fund's option strategy.
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.